PTC Therapeutics Q2 revenue more than doubles, raises 2026 outlook

PTC Therapeutics

30/07/2026 21:13

Overview
U.S. biopharma firm's Q2 total revenue more than doubled yr/yr, driven by product sales
Company swung to Q2 net profit from loss a year ago
Full-year 2026 revenue and product revenue guidance raised

Outlook
PTC raises 2026 total revenue guidance to $1.18-$1.28 bln
Company raises 2026 product revenue guidance to $850-$950 mln from $750-$850 mln
PTC maintains 2026 GAAP R&D and SG&A expense guidance at $775-$815 mln

Result Drivers
SEPHIENCE UPTAKE - Growth in product revenue was led by Sephience, which generated $151 mln in Q2 sales with broad uptake and international expansion
MILESTONE PAYMENT - Q2 results included a $50 mln milestone payment from Novartis for the first patient dosed in the INVEST-HD Phase 3 study
HIGHER ROYALTIES - Royalty revenue from Roche's Evrysdi rose to $71.1 mln in Q2, up from $57.6 mln a year earlier

Company press release: ID:nPnBhBY0a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$238.82 mln
 
Q2 EPS
 
$0.92
 
Q2 Net Income
 
$83.50 mln
 
Q2 Basic EPS
 
$1.01
 
Q2 Operating Expenses
 
$211.54 mln
 
Q2 Operating Income
 
$148.98 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PTC Therapeutics Inc is $93.00, about 24.8% above its July 29 closing price of $74.49

Reuters Recommended Reads
July 30 - Alnylam Q2 revenue rises 67% on increased demand for AMVUTTRA
July 30 - Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
July 30 - Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)